Piperacillin plus aztreonam for treatment of neutropenic fever

Pediatrics International

Volumn 45, Issue 3, 2003, Pages 307-310

  Takeuchi, Motohiro ^a,b   Tanizawa, Akihiko ^a   Mayumi, Mitsufumi ^a  

^a University of Fukui   (Japan)

^b NONE   (Japan)

Author keywords

Alpha streptococcus; Aztreonam; Neutropenic fever; Piperacillin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; PIPERACILLIN;

ADOLESCENT; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTEREMIA; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MIXTURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZTREONAM; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; INFANT; MALE; NEOPLASMS; NEUTROPENIA; PENICILLINS; PIPERACILLIN;

EID: 0041662152     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01715.x     Document Type: Article

References (37)

1. Pizzo PA. Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 1984; 54: 2649-61.
2. Hughes WT, Armstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin. Infect. Dis. 1997 1997; 25: 551-73.
3. Neu HC. Aztreonam activity, pharmacology, and clinical uses. Am. J. Med. 1990; 88 (Suppl. 3c): 2-6.
4. Parry MF. Aztreonam susceptibility testing. A retrospective analysis. Am. J. Med. 1990; 88 (Suppl. 3c): 7-11.
5. Rolston KV, Bodey GP, Elting L. Aztreonam in the prevention and treatment of infection in neutropenic cancer patients. Am. J. Med. 1990; 88 (Suppl. 3c) 24-9.
6. Lebel MH, McCracken GH Jr. Aztreonam: review of the clinical experience and potential uses in pediatrics. Pediatr. Infect. Dis. J. 1988; 7: 331-9.
7. Adkinson NF Jr. Immunogenicity and cross-allergenicity of aztreonam. Am. J. Med. 1990; 88 (Suppl. 3c): 12-15.
8. Bodey G, Reuben A, Elting L et al. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J. Clin. Microbiol. Infect. Dis. 1991; 10: 551-8.
9. Murase T. Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases. Kansenshogaku Zasshi 1992; 66: 121-6.
10. Fishman A, Chowers M, Altaras M, Beyth Y, Lang R. Aztreonam plus piperacillin: empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy. Eur. J. Gynaecol. Oncol. 1998; 19: 126-9.
11. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann. Intern. Med. 1994; 120: 834-44.
12. Feliu J, Artal A, Gonzalez Baron M, Berrocal A, Chacon I. Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer. Antimicrob. Agents Chemother. 1992; 36: 2816-20.
13. Meunier F, Zinner SH, Gaya H et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob. Agents Chemother. 1991; 35: 873-8.
14. Kelsey SM, Wood ME, Shaw E, Jenkins JC, Newland AC. A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. J. Antimicrob. Chemother. 1990; 25: 149-57.
15. Leyland MJ, Bayston KF, Cohen J et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J. Antimicrob. Chemother. 1992; 30: 843-54.
16. Sampi K, Hattori M. Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study. Gan Kagaku Ryoho. 1992; 19: 1315-20.
17. Herbrecht R., Damonte JC, Bergerat JP et al. Piperacillin and netilmicin combination therapy for febrile episodes in neutropenic patients. Infection 1990; 18: 310-13.
18. Kelsey SM, Collins PW, Delord C, Weinhard B, Newland AC. A randomized study of teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients. Br. J. Haematol. 1990; 76 (Suppl. 2): 10-13.
19. Martino P, Micozzi A, Gentile G, Raccah R, Girmenia C, Mandelli F. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin. Infect. Dis. 1992; 15: 290-94.
20. Kelsey SM, Weinhardt B, Collins PW, Newland AC. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 1992; 11: 509-14.
21. Rdgers TR. Management of septicaemia in the immunocompromised with particular reference to neutropenic patients. In: Shanson, DC (ed.) Septicaemia and Endocarditis. Clinical and Microbiological Aspects. Oxford Scientific Publications, Oxford, 1990: p113-42.
22. Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am. J. Med. 1987; 82: 723-30.
23. Steiner M. Villablanca J, Kersey J et al. Viridans streptococcal shock in bone marrow transplantation patients. Am. J. Hematol. 1993; 42: 354-8.
24. Cohen J, Donnelly JP, Worsley AM, Catovsky D, Goldman JM, Galton DA. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet 1983; 2: 1452-4.
25. Bochud PY, Eggiman P, Calandra T, Melle GV, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin. Infect. Dis. 1994; 18: 25-31.
26. Pizzo PA, Ladisch S, Witebsky FG. Alpha-hemolytic streptococci: clinical significance in the cancer patient. Med. Pediatr. Oncol. 1978; 4: 367-70.
27. Etienne J, Vandenesch F, Fauvel JP, Coulet M, Brun Y, Fleurette J. Susceptibilities to ceftriaxone of streptococcal strains associated with infective endocarditis. Chemotherapy 1989; 35: 355-9.
28. Wilcox MH, Winstanley TG, Douglas CW, Spencer RC. Susceptibility of alpha-haemolytic streptococci causing endocarditis to benzylpenicillin and ten cephalosporins. J. Antimicrob. Chemother. 1993; 32: 63-9.
29. Pierard D, de Meyer A, Lauwers S. Antibiotic susceptibility of streptococci isolated from blood from neutropenic patients. Pathol Biol. (Paris) 1994; 42: 471-4.
30. Alcaide F, Linares J, Pallares R, Carratala J, Benitez MA, Gudiol F. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob. Agents Chemother. 1995; 39: 2243-7.
31. Pfaller MA, Jones RN. In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci. Diagn. Microbiol. Infect. Dis. 1997; 27: 151-4.
32. Jones RN, Wilson WR. Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. Diagn. Microbiol. Infect. Dis. 1998; 31: 453-9.
33. Traub WH, Leonhard B. Antibiotic susceptibility of alpha- and nonhemolytic streptococci from patients and healthy adults to 24 antimicrobial drugs. Chemotherapy 1997; 43: 123-31.
34. Tasaka T, Nagai M, Sasaki K. et al. Streptococcus mitis septicemia in leukemia patients; clinical features and outcome. Intern. Med. 1993; 32: 221-4.
35. Seifert H. Comparative in vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates. Zentralbl Bakteriol. 1998; 288: 509-518.
36. Wiseman LR, Lamb HM. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997; 54: 117-40.
37. Martinez-Beltran J, Canton R, Linares J et al. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin. Eur. J. Clin. Microbiol. Infect. Dis. 1995; 14: 244-52.